Bryant AK, et al. - Whether 3-month post-radiotherapy (RT) prostate-specific antigen (PSA) level is associated with biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS) in patients with intermediate-risk and high-risk prostate cancer was investigated. Researchers examined cases, identified from Veterans Affairs data, treated with RT and androgen deprivation. Three-month post-RT PSA values used to divide patients into groups. To assess the links, they used multivariable Cox models adjusting for potential confounders. They found that in these patients, specifically those with high-risk disease, 3-month post-RT PSA level appeared to be a strong predictive biomarker for bPFS, PCSS, and OS.